Hsa-miR-375 is a predictor of local control in early stage breast cancer

Zehentmayr, Franz; Hauser-Kronberger, Cornelia; Zellinger, Barbara; Hlubek, Falk; Schuster, Claudia; Bodenhofer, Ulrich; Fastner, Gerd; Deutschmann, Heinz; Steininger, Philipp; Reitsamer, Roland; Fischer, Thorsten; Sedlmayer, Felix

doi:10.1186/s13148-016-0198-1

Clinical Epigenetics

Table 1 Patient and treatment characteristics

From: Hsa-miR-375 is a predictor of local control in early stage breast cancer

Patient and treatment characteristics
Parameters		Pilot phase n = 32			Validation phase n = 115
Parameters		Relapse n = 16	Control n = 16	p value	Relapse n = 30	Control n = 85	p value
Age at diagnosis (years)	Median	53.5	52	0.88	52	54	0.59
Age at diagnosis (years)	Range	36–71	35–74	0.88	33–79	37–78	0.59
Menopause (n)	No	4 (25 %)	4 (25 %)	1.0	11 (36.7 %)	32 (37.6 %)	0.37
	Yes	8 (50 %)	8 (50 %)		17 (56.7 %)	40 (47.1 %)
	Unclear	4 (25 %)	4 (25 %)		2 (6.7 %)	13 (15.3 %)
T (n)	T1	10 (62.5 %)	10 (62.5 %)	1.0	26 (86.7 %)	75 (88.2 %)	0.82
T (n)	T2	6 (37.5 %)	6 (37.5 %)	1.0	4 (13.3 %)	10 (11.8 %)	0.82
N (n)	N0	13 (81.3 %)	13 (81.3 %)	1.0	24 (80 %)	67 (78.8 %)	0.88
	N1	2 (12.5 %)	2 (12.5 %)		6 (20 %)	18 (21.1 %)
	N2	1 (6.3 %)	1 (6.3 %)		0	0
M (n)	M0	16 (100 %)	16 (100 %)	1.0	30 (100 %)	85 (100 %)	1.0
M (n)	M1	0	0	1.0	0	0	1.0
Grading (n)	G1	1 (6.3 %)	0	0.87	3 (10 %)	8 (9.4 %)	0.75
	G2	8 (50 %)	9 (56.3 %)		18 (60 %)	55 (64.7 %)
	G3	7 (43.8 %)	7 (43.8 %)		9 (30 %)	22 (25.9 %)
Histology (n)	IDC	13 (81.3 %)	15 (93.8 %)	0.56	22 (73.3 %)	63 (74.1 %)	0.98
	ILC	3 (18.8 %)	1 (6.3 %)		5 (16.7 %)	12 (14.1 %)
	Tubular	0	0		2 (6.7 %)	6 (7.1 %)
	Other	0	0		1 (3.3 %)	4 (4.7 %)
In situ component (n)	Yes	14 (87.5 %)	10 (62.5 %)	0.24	17 (56.7 %)	47 (55.3 %)	0.97
	No	2 (12.5 %)	6 (6.25 %)		13 (43.3 %)	35 (41.2 %)
	Lymphangiosis	0	0		0	1 (1.2 %)
	Not stated	0	0		0	2 (2.4 %)
Receptors (n)	ER positive	8 (50 %)	10 (62.5 %)	0.56	23 (76 %)	67 (78.8 %)	0.81
	ER negative	8 (50 %)	6 (37.5 %)	0.56	7 (23.3 %)	18 (21.2 %)	0.81
	PR positive	8 (50 %)	8 (50 %)	0.56	19 (63.3 %)	62 (72.9 %)	0.32
	PR negative	8 (50 %)	8 (50 %)	0.56	11 (36.7 %)	23 (27.1 %)	0.32
her2neu	Positive	8 (50 %)	4 (25 %)	0.24	11 (37 %)	24 (28 %)	0.81
	Negative	5 (31 %)	9 (56 %)		18 (60 %)	44 (52 %)
	Not assessable	3 (19 %)	3 (19 %)		1 (3 %)	17 (20 %)
Proliferation index	ki67 < 20 %	10 (63 %)	6 (38 %)	0.24	15 (50 %)	49 (58 %)	0.78
	ki67 > 20 %	5 (31 %)	9 (56 %)		10 (33 %)	26 (31 %)
	Not assessable	1 (6 %)	1 (6 %)		5 (17 %)	10 (11 %)
Boost (n)	Intraoperative	8 (50 %)	8 (50 %)	1.0	11 (36.7 %)	34 (40 %)	0.91
	Percutaneous	8 (50 %)	8 (50 %)		16 (53.3 %)	51 (60 %)
	None	0	0		3 (10 %)	0
Boost dose (Gy)	Dose intraoperative	10 Gy	10 Gy	0.84	10 Gy	10 Gy	0.58
Boost dose (Gy)	Dose percutaneous	12 Gy	12 Gy	0.84	12 (15–19) Gy	12 (9–19) Gy	0.58
WBRT dose (Gy)	Median	54 Gy	54 Gy	0.78	54 Gy	54 Gy	0.68
WBRT dose (Gy)	Range	51.2–61.2 Gy	51.2–57.8 Gy	0.78	51–63 Gy	51–57.6 Gy	0.68
Surgery (n)	BCT	16 (100 %)	15 (93.8 %)	0.78	30 (100 %)	85 (100 %)	1.0
Surgery (n)	Mastectomy	0	1 (6.3 %)	0.78	0	0	1.0
Re-Excisition (n)	Yes	8 (50 %)	4 (25 %)	0.24	12 (40 %)	33 (38.8 %)	0.91
Re-Excisition (n)	No	8 (50 %)	12 (75 %)	0.24	18 (60 %)	52 (61.2 %)	0.91
Year of surgery (n)	Before 1998	5 (31.3 %)	5 (31.3 %)	1.0	14 (46.7 %)	38 (44.7 %)	0.85
Year of surgery (n)	Since 1998	11 (68.8 %)	11 (68.8 %)	1.0	16 (53.3 %)	47 (55.3 %)	0.85
Chemotherapy (n)	Yes	8 (50 %)	6 (37.5 %)	0.56	11 (36.7 %)	20 (23.5 %)	0.18
Chemotherapy (n)	No	8 (50 %)	10 (62.5 %)	0.56	19 (63.3 %)	65 (76.5 %)	0.18
Hormonal treatment (n)	Yes	8 (50 %)	7 (43.8 %)	0.78	16 (53.3 %)	56 (65.9 %)	0.27
	No	8 (50 %)	9 (56.3 %)		13 (43.3 %)	26 (30.6 %)
	Unclear	0	0		1 (3.3 %)	3 (3.5 %)
Tumor burden in biopsy (%)	Median	70	50	0.34	70	50	0.52
Tumor burden in biopsy (%)	Range	10–90	10–90	0.34	10–90	10–90	0.52

Patient and treatment characteristics as well as the relative tumor burden in the samples are shown. The relapse group and control were compared with the Mann-Whitney U test. Neither in the pilot nor in the validation phase statistically significant differences of potentially prognostic parameters were detected between the relapse and the control group. The stainings for her2 and ki-67 were performed according to the standard procedures implemented at the Department of Pathology. Because some of the specimens were quite old (minimum 5 years) in some cases, the stainings—even on repetition—did not yield valid result due to technical problems with the non-adhesive FFPE sections

Back to article page

ISSN: 1868-7083

Contact us

Submission enquiries: avalyn.villar@springernature.com
General enquiries: info@biomedcentral.com